SOURCE: Applied Nanoscience, Inc.

March 05, 2008 10:49 ET

Applied Nanoscience Issues Progress Report

CARLSBAD, CA--(Marketwire - March 5, 2008) - Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN) today issued the following progress report:

Testing of filter samples incorporating the company's proprietary silver nanoparticle formulation were tested after a simulated one-year aging process and proved to be highly effective in eradicating avian influenza. An independent BSL-3 laboratory reported a 3.6 log reduction (equivalent to a 99.96% reduction) in the avian influenza simulant H9N2 when exposed to the one-year aged nanoparticle enhanced filter media.

The technology, which has been under development for the past several years, has demonstrated effectiveness against a broad range of other pathogens, such as Staphylococcus aureus, Streptococcus pneumoniae, and the drug resistant S. aureus MRSA.

"We are very encouraged at the sustained progress made with our Nanoparticle - Enhanced - Filtration - Technology platform. The continued focus of our scientific team to include recent scale-up success has put us in a position to begin targeting license partners in a number of consumer markets," said Thomas Allen, President and CEO, ANI.

On February 8, 2008 Applied Nanoscience filed a Form 10-SB under Section 12(g) of The Securities Exchange Act of 1934 to become a fully reporting company. Filing this document one of the necessary steps the company must take to advance to the OTC Bulletin Board (OTCBB). An eventual listing on the OTCBB is expected to enhance the company's profile in public equity markets and make it easier to attract financing.

Applied Nanoscience Inc. is a marketer and developer of innovative, high-performance filtration products, systems and technologies to customers worldwide in a focused effort to provide a safer tomorrow.

For further information about Applied Nanoscience Inc., please visit: www.appliednanoscience.com

Contact Information